Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1995 6
1996 3
1997 2
1998 2
1999 1
2000 2
2002 1
2003 1
2008 1
2014 1
2016 2
2019 1
2020 1
2021 1
2022 1
2024 2
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Hormonal intrauterine devices.
Rybo G, Andersson K, Odlind V. Rybo G, et al. Ann Med. 1993 Apr;25(2):143-7. doi: 10.3109/07853899309164158. Ann Med. 1993. PMID: 8489751
Intrauterine administration of progestogens is also effective in opposing the proliferative effect of oestrogen on the endometrium in women on hormonal replacement therapy. The levonorgestrel (LNg) IUD releases 20 mcg LNg/day and protects against pregn …
Intrauterine administration of progestogens is also effective in opposing the proliferative effect of oestrogen on the endometrium in women …
Heavy Menstrual Bleeding and Hormonal Therapy in Women with Type 1 von Willebrand Disease Enrolled on the Zimmerman Program.
Machin N, Navarrete A, Rothenberger S, Flood V, Christopherson P, Montgomery R, Ragni MV; Zimmerman Program Investigators. Machin N, et al. Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251359294. doi: 10.1177/10760296251359294. Epub 2025 Jul 14. Clin Appl Thromb Hemost. 2025. PMID: 40660798 Free PMC article.
Of these, 103 were hormone users, including oral contraceptives (71), medroxyprogesterone acetate (11), levonorgestrel IUD (11), contraceptive implant (3), and the etonogestrel/ethinyl estradiol vaginal ring (1) and (6) subjects were undergoing hormone …
Of these, 103 were hormone users, including oral contraceptives (71), medroxyprogesterone acetate (11), levonorgestrel IUD …
Noncontraceptive health benefits of intrauterine devices: a systematic review.
Hubacher D, Grimes DA. Hubacher D, et al. Obstet Gynecol Surv. 2002 Feb;57(2):120-8. doi: 10.1097/00006254-200202000-00024. Obstet Gynecol Surv. 2002. PMID: 11832788 Free article.
We conducted a series of systematic literature searches to identify articles on the noncontraceptive health benefits of IUD use. We reviewed the potentially pertinent ones for content, grouped them according to type of IUD, and evaluated them using the U.S. ...The …
We conducted a series of systematic literature searches to identify articles on the noncontraceptive health benefits of IUD use. We r …
Frequent Use of Premenopausal Progestin in Women With Prior Preeclampsia.
Joensuu JM, Ylikorkala O, Venetkoski M, Gissler M, Savolainen-Peltonen H, Mikkola TS. Joensuu JM, et al. J Clin Endocrinol Metab. 2025 Jun 17;110(7):1946-1951. doi: 10.1210/clinem/dgae677. J Clin Endocrinol Metab. 2025. PMID: 39376025 Free PMC article.
OBJECTIVE: We compared the use of cyclic progestins or levonorgestrel-releasing intrauterine device (LNG-IUD) for treatment of menstrual cycle abnormalities between premenopausal women with and without a prior preeclamptic pregnancy. ...Cyclic progestin or LNG-IU …
OBJECTIVE: We compared the use of cyclic progestins or levonorgestrel-releasing intrauterine device (LNG-IUD) for treatment of …
A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F, Guillebaud J. Sturridge F, et al. Drug Saf. 1996 Dec;15(6):430-40. doi: 10.2165/00002018-199615060-00006. Drug Saf. 1996. PMID: 8968696 Review.
The low dosage of levonorgestrel released by its unique delivery system ensures minimal hormone-related systemic adverse effects, which tend to be in the category of 'nuisance' rather than hazardous, and gradually diminish after the first few months of use. ...A pro …
The low dosage of levonorgestrel released by its unique delivery system ensures minimal hormone-related systemic adverse effec …
[Hormones and mammographic breast density].
Boisserie-Lacroix M, Lebiez-Michel N, Cavagni P, Bentolila J, Laumonier H, Bouzgarrou M, Trillaud H. Boisserie-Lacroix M, et al. J Radiol. 2008 Sep;89(9 Pt 2):1196-203. doi: 10.1016/s0221-0363(08)73930-1. J Radiol. 2008. PMID: 18772804 Review. French.
Breast constitutional density may be altered and increased (acquired density) by hormonal interventions such as hormone replacement therapy (HRT). The effects of endogenous (steroids, prolactin, insulin-like factors...) and exogenous (HRT, levonorgestrel …
Breast constitutional density may be altered and increased (acquired density) by hormonal interventions such as hormone replacemen …
Endometriosis: an overview of Cochrane Reviews.
Brown J, Farquhar C. Brown J, et al. Cochrane Database Syst Rev. 2014 Mar 10;2014(3):CD009590. doi: 10.1002/14651858.CD009590.pub2. Cochrane Database Syst Rev. 2014. PMID: 24610050 Free PMC article.
There was moderate quality evidence that the levonorgestrel-releasing intrauterine system (LNG-IUD) was more effective than expectant management, and very low quality evidence that danazol was more effective than placebo. ...AUTHORS' CONCLUSIONS: For women with pain …
There was moderate quality evidence that the levonorgestrel-releasing intrauterine system (LNG-IUD) was more effective than ex …
Intrauterine device use in adolescence: a narrative review.
Zoi A, Vatopoulou A, Skentou X, Tsonis O, Galaziou G, Koutalia N, Margariti K, Chatzisavva E, Paschopoulos M, Gkrozou F. Zoi A, et al. Minerva Obstet Gynecol. 2025 Feb;77(1):45-55. doi: 10.23736/S2724-606X.24.05405-8. Epub 2024 Oct 8. Minerva Obstet Gynecol. 2025. PMID: 39377286 Review.
Intrauterine devices are part of the long-acting reversible contraceptives (LARCs) and include the copper bearing device (CU-IUD) and the levonorgestrel intrauterine system (LNG-IUS). IUDs are a safe and effective contraceptive method for adolescents with a failure …
Intrauterine devices are part of the long-acting reversible contraceptives (LARCs) and include the copper bearing device (CU-IUD) and …
Femilis( ) 60 Levonorgestrel-Releasing Intrauterine System-A Review of 10 Years of Clinical Experience.
Wildemeersch D, Andrade A, Goldstuck N. Wildemeersch D, et al. Clin Med Insights Reprod Health. 2016 Aug 9;10:19-27. doi: 10.4137/CMRH.S40087. eCollection 2016. Clin Med Insights Reprod Health. 2016. PMID: 27547046 Free PMC article. Review.
STUDY DESIGN: Using the Femilis 60 LNG-IUS releasing 20 g of levonorgestrel/day, the following studies were conducted: an open, prospective noncomparative contraceptive study, an MBL study, a perimenopausal study, a study for the treatment of endometrial hyperplasia, and …
STUDY DESIGN: Using the Femilis 60 LNG-IUS releasing 20 g of levonorgestrel/day, the following studies were conducted: an open, pro …
Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
Suvanto-Luukkonen E, Malinen H, Sundström H, Penttinen J, Kauppila A. Suvanto-Luukkonen E, et al. Acta Obstet Gynecol Scand. 1998 Aug;77(7):758-63. Acta Obstet Gynecol Scand. 1998. PMID: 9740525
This study evaluated the endometrial morphological response to the levonorgestrel-releasing IUD (LNG-IUD) and to natural progesterone administered orally or vaginally in postmenopausal women using percutaneous estradiol gel on a daily basis. The study employe …
This study evaluated the endometrial morphological response to the levonorgestrel-releasing IUD (LNG-IUD) and to natura …
32 results